N,N-Dimethyltryptamine - Biomind Labs
Alternative Names: BMND-01; BMND-02; BMND-03Latest Information Update: 28 Oct 2025
At a glance
- Originator Biomind Labs
- Class Antidepressants; Antipsychotics; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
- Mechanism of Action Neuron modulators; Serotonin 5-HT2A receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Treatment-resistant depressive disorder
- No development reported Fibromyalgia; Substance-related disorders
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Substance-related disorders in Canada
- 28 Jun 2025 No recent reports of development identified for phase-I development in Fibromyalgia in Unknown
- 28 Sep 2024 No recent reports of development identified for phase-I development in Treatment resistant depressive disorder in Canada (Inhalation)